Less than one in 10 patients that would benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it releases its first advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for increased and just access to these injectable treatments.
According to projections, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our new guidelines affirms that obesity is a long-term condition that can be addressed with thorough and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant barriers to broad access to the treatments that can assist patients in reducing significant weight, says the body.
Skinny Jab Supply Crisis
Even in the present most optimistic scenario, the supply of these medications could only cover around 100 million people – fewer than 10% of eligible patients, per the WHO.
The recommendation calls on countries and companies to widen availability, via strategies like licensing agreements.
Exclusive production rights on a key compound – the core ingredient of a leading brand – is due to expire in several countries in 2026.
The Way Obesity Injections Work
These medications imitate a body's own hormone to reduce digestion speed, curb appetite and boost the sense of being full so people reduce food intake.
Individuals usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Research points to people may put most of the weight back on a year later of halting the drug, when their normal food cravings come back.
Being above a healthy weight raises your chance for experiencing diseases, like type 2 diabetes, heart disease, stroke, and certain cancers.
Excess weight affects people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
